Should we add screening for and treating left ventricular hypertrophy to the management of all patients needing secondary prevention of cardiovascular disease?

QJM: An International Journal of Medicine

Volumn 96, Issue 6, 2003, Pages 449-452

  Struthers, A D ^a   Davies, J ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; LOSARTAN; RAMIPRIL;

ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; HEALTH CARE DELIVERY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MEDICAL RESEARCH; PATIENT CARE; PRIORITY JOURNAL; REMISSION; RISK FACTOR; RISK MANAGEMENT; SCREENING TEST; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK;

EID: 0038621327     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg067     Document Type: Article

References (18)

1. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined LV mass in the Framingham heart study. N Engl J Med 1990; 322:1561-6.
2. Ghali JK, Liao Y, Simmons B, et al. The Prognostic role of LVH in patients with or without coronary artery disease. Ann Intern, Med 1992; 177:831-6.
3. Liao Y, Cooper RS, McGee DL, et al. The relative effects of LVH, coronary artery disease and ventricular dysfunction on survival among black adults. JAMA 1995; 273:1592-7.
4. Levy D, Anderson, KM, Savage DD, et al. Echocardiographically detected LVH: prevalence and risk factors: the Framingham heart study. Ann Intern Med 1988; 108:7-13.
5. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-7.
6. Rana BS, Band M, Pringle SD, et al. Relation of QT dispersion to underlying cardiac abnormalities in diabetes mellitus. Am J Cardiol 2002; 90:483-7.
7. Phillips RA, Krakoff LR, Dunaif A, Finegood DT, Gorlin R, Schimabukuro S. Relation among LV mass, insulin resistance and BP in non-obese subjects. J Clin Endocrinol Metab 1998; 83:4284-88.
8. Chen CH, Ting CT, Lin SJ, Hsu TL, Ho SJ, Chou P, et al. Which arterial and cardiac parameters best predict left ventricular mass? Circulation 1998; 98:422-8.
9. Bella JN, Devereux RB, Roman JM, O'Grady MJ, Paranicas M, Yeh JL, et al. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation 1997; 96: 1416-23.
10. Devereux RB, Roman MJ, de Simone G, O'Grady MJ, Paranicas M, Yel JL, et al. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation 1997; 96:1416-23.
11. Verdecchia P, Schillaci G, Botgioni C, Ciucci A, Gattobigio R, Zamp I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
12. Levy D, Salomon M, Agostino RB, et al. Prognostic implications of baseline ECG features and their serial changes in subjects with LVH. Circulation 1994; 90:1786-93.
13. Muiesan ML, Salvetti M, Rizzioni D, et al. Association of change in LV mass with prognosis during long term antihypertensive treatment. J Hyper 1995; 13:1091-5.
14. Yurenev AP, Dyakonova HG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of LVH: multicenter trial. Am J Hypertens 1992; 5(pt 2):182-9S.
15. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
16. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of let ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104:1615-21.
17. Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals. Lancet 2002; 360:7-22.
18. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in LV mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 1995; 91:698-706.